Data Insights

Vobramitamab duocarmazine by MacroGenics for Castration-Resistant Prostate Cancer (CRPC): Likelihood of Approval

Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Castration-Resistant Prostate Cancer (CRPC). According to...

Data Insights

Vobramitamab duocarmazine by MacroGenics for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...

Data Insights

Vobramitamab duocarmazine by MacroGenics for Ovarian Cancer: Likelihood of Approval

Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...

Data Insights

Vobramitamab duocarmazine by MacroGenics for Melanoma: Likelihood of Approval

Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Melanoma. According to GlobalData, Phase II...

Data Insights

Vobramitamab duocarmazine by MacroGenics for Castration-Resistant Prostate Cancer (CRPC): Likelihood of Approval

Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Castration-Resistant Prostate Cancer (CRPC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Vobramitamab Duocarmazine in Castration-Resistant Prostate Cancer (CRPC)

Data Insights

Vobramitamab duocarmazine by MacroGenics for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...

Likelihood of Approval and Phase Transition Success Rate Model - Vobramitamab Duocarmazine in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data Insights

Vobramitamab duocarmazine by MacroGenics for Pancreatic Cancer: Likelihood of Approval

Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Vobramitamab Duocarmazine in Pancreatic Cancer

Data Insights

Vobramitamab duocarmazine by MacroGenics for Hepatocellular Carcinoma: Likelihood of Approval

Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Vobramitamab Duocarmazine in Hepatocellular Carcinoma

Data Insights

Vobramitamab duocarmazine by MacroGenics for Renal Cell Carcinoma: Likelihood of Approval

Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Renal Cell Carcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Vobramitamab Duocarmazine in Renal Cell Carcinoma

Data Insights

Vobramitamab duocarmazine by MacroGenics for Small-Cell Lung Cancer: Likelihood of Approval

Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Vobramitamab Duocarmazine in Small-Cell Lung Cancer

Data Insights

Vobramitamab duocarmazine by MacroGenics for Anal Cancer: Likelihood of Approval

Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Anal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Vobramitamab Duocarmazine in Anal Cancer

Data Insights

Vobramitamab duocarmazine by MacroGenics for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Head And Neck Squamous Cell Carcinoma...

Likelihood of Approval and Phase Transition Success Rate Model - Vobramitamab Duocarmazine in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

Vobramitamab duocarmazine by MacroGenics for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval

Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Vobramitamab Duocarmazine in Squamous Non-Small Cell Lung Cancer